Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
Protagenic Therapeutics, Inc.\new (PTIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 4.00 thousand shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2023-03-31
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-12-31 was -12.00K shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-09-30 was 0.00 shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-06-30 was 0.00 shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2022-03-31 was 16.00K shares.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2022 was 4.00K shares, a 99.56% decline from fiscal 2021.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2021 was 914.25K shares, a 406.79% increase from fiscal 2020.
- Protagenic Therapeutics, Inc.\new share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2020 was 180.40K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | -12.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -12.00K shares derived: sum of 2 quarters · filed 2023-03-31 | -12.00K shares derived: sum of 3 quarters · filed 2023-03-31 | 4.00K shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-14 | 16.00K shares 10-Q · filed 2022-11-14 | -2.73M shares derived: sum of 4 quarters · filed 2023-03-31 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 16.00K shares 10-Q · filed 2022-08-11 | -2.73M shares derived: sum of 3 quarters · filed 2023-03-31 | -2.73M shares derived: sum of 4 quarters · filed 2023-03-31 | |
| 2022-03-31 | 16.00K shares 10-Q · filed 2022-05-13 | -2.73M shares derived: sum of 2 quarters · filed 2023-03-31 | -2.73M shares derived: sum of 3 quarters · filed 2023-03-31 | ||
| 2021-12-31 | -2.74M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -2.74M shares derived: sum of 2 quarters · filed 2023-03-31 | 914.25K shares 10-K · filed 2023-03-31 | 3.66M shares 10-K · filed 2022-04-07 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 3.66M shares 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 3.66M shares 10-Q · filed 2021-08-16 | ||||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 98.80K shares derived: sum of 2 quarters · filed 2021-03-25 | 180.40K shares 10-K · filed 2021-03-25 | ||
| 2020-09-30 | 98.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | 180.40K shares 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | 81.60K shares 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |